Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Pule

Showing results (21-30 of 77) with videos related to

Pageof 8
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 30, 2009
2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cellsBianca Altvater, Silke Landmeier, Sibylle Pscherer, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 10, 2011
In vitro comparison of three different chimeric receptor-modified effector T-cell populations for leukemia cell therapyIrene Pizzitola, Valentina Agostoni, Elisabetta Cribioli, et al.
Blood|November 13, 2004
Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytesEttore Biagi, Gianpietro Dotti, Eric Yvon, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 21, 2005
Target antigen expression on a professional antigen-presenting cell induces superior proliferative antitumor T-cell responses via chimeric T-cell receptorsClaudia Rossig, Annette Bär, Sibylle Pscherer, et al.
British Journal of Haematology|December 20, 2015
Treatment of diffuse large B-cell lymphoma with secondary central nervous system involvement: encouraging efficacy using CNS-penetrating R-IDARAM chemotherapyPaul Maciocia, Mohsin Badat, Simon Cheesman, et al.
Molecular Therapy. Nucleic Acids|May 18, 2023
Novel Fas-TNFR chimeras that prevent Fas ligand-mediated kill and signal synergistically to enhance CAR T cell efficacyCallum McKenzie, Mohamed El-Kholy, Farhaan Parekh, et al.
Blood|February 17, 2005
Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosisGianpietro Dotti, Barbara Savoldo, Martin Pule, et al.
Vaccines|February 13, 2021
Engineering a Human Plasmacytoid Dendritic Cell-Based Vaccine to Prime and Expand Multispecific Viral and Tumor Antigen-Specific T-CellsKevin Lenogue, Alexandre Walencik, Karine Laulagnier, et al.
Blood|November 6, 2009
Functional characterization of alloreactive T cells identifies CD25 and CD71 as optimal targets for a clinically applicable allodepletion strategySujith Samarasinghe, Christoph Mancao, Martin Pule, et al.
Oncoimmunology|January 27, 2017
T-helper cell receptors from long-term survivors after telomerase cancer vaccination for use in adoptive cell therapyJon Amund Kyte, Gustav Gaudernack, Anne Faane, et al.
Pageof 8

Showing results (21-30 of 77) with videos related to

Sort By:
Pageof 8
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 30, 2009
2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cellsBianca Altvater, Silke Landmeier, Sibylle Pscherer, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 10, 2011
In vitro comparison of three different chimeric receptor-modified effector T-cell populations for leukemia cell therapyIrene Pizzitola, Valentina Agostoni, Elisabetta Cribioli, et al.
Blood|November 13, 2004
Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytesEttore Biagi, Gianpietro Dotti, Eric Yvon, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 21, 2005
Target antigen expression on a professional antigen-presenting cell induces superior proliferative antitumor T-cell responses via chimeric T-cell receptorsClaudia Rossig, Annette Bär, Sibylle Pscherer, et al.
British Journal of Haematology|December 20, 2015
Treatment of diffuse large B-cell lymphoma with secondary central nervous system involvement: encouraging efficacy using CNS-penetrating R-IDARAM chemotherapyPaul Maciocia, Mohsin Badat, Simon Cheesman, et al.
Molecular Therapy. Nucleic Acids|May 18, 2023
Novel Fas-TNFR chimeras that prevent Fas ligand-mediated kill and signal synergistically to enhance CAR T cell efficacyCallum McKenzie, Mohamed El-Kholy, Farhaan Parekh, et al.
Blood|February 17, 2005
Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosisGianpietro Dotti, Barbara Savoldo, Martin Pule, et al.
Vaccines|February 13, 2021
Engineering a Human Plasmacytoid Dendritic Cell-Based Vaccine to Prime and Expand Multispecific Viral and Tumor Antigen-Specific T-CellsKevin Lenogue, Alexandre Walencik, Karine Laulagnier, et al.
Blood|November 6, 2009
Functional characterization of alloreactive T cells identifies CD25 and CD71 as optimal targets for a clinically applicable allodepletion strategySujith Samarasinghe, Christoph Mancao, Martin Pule, et al.
Oncoimmunology|January 27, 2017
T-helper cell receptors from long-term survivors after telomerase cancer vaccination for use in adoptive cell therapyJon Amund Kyte, Gustav Gaudernack, Anne Faane, et al.
Pageof 8